Adlai Nortye Ltd. American Depositary Shares (ANL)

USD 2.14

(1.42%)

Market Cap (In USD)

66.84 Million

Revenue (In USD)

4.99 Million

Net Income (In USD)

-104.87 Million

Avg. Volume

8169.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.85-17.48
PE
-
EPS
-
Beta Value
6.2780385
ISIN
US00704R1095
CUSIP
-
CIK
1944552
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Yang Lu
Employee Count
-
Website
https://www.adlainortye.com
Ipo Date
2023-09-23
Details
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.